Osivax is developing OVX836, a global influenza vaccine that targets the virus’s nucleoprotein (NP). Because the NP is highly conserved and less prone to changes than surface antigens, the vaccine may not require yearly updates. The findings of Phase 2a research on OVX836 were recently published in The Lancet Infectious Diseases journal. OVX836 was tested in 137 healthy individuals for safety, immunogenicity, and preliminary effectiveness. At all dosage levels tested, the vaccine was proven to be safe and immunogenic, inducing both antibody and T-cell immune responses against the NP. Notably, OVX836 elicited CD8+ T-cell responses, which are difficult to induce in protein vaccines and are seldom observed. In addition, compared to placebo, the vaccination had an 84% efficiency against symptomatic influenza.

To know more: About the original article click here.